drugset / Trial / NCT06128837
Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter，randomized, open label, active-controlled, parallel-group study comparing efficacy and safety of LY01610(Irinotecan hydrochloride liposome Injection) and Topotecan in Patients with Recurrent Small Cell Lung Cancer (SCLC)
Timeline
- Start
- 2024-03-03
- Primary completion
- 2028-06
- Completion
- 2028-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 80 mg/m2 | Intravenous |
| Comparator | Topotecan | Small molecule | 1.2 mg/m2 | Intravenous |